Replimune shares gained ahead of its fourth-quarter earnings report, following positive human-trial data of its immunotherapy ...

Replimune (REPL) stock dips as the FDA plans an advisory committee meeting after accepting the company's marketing ...

Replimune stock surges after the company aligned with the FDA on plans to resubmit its BLA for RP1 plus Opdivo in advanced ...

Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, announced today that the U.S. Food and Drug Administration ...

Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal fourth ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

) has been revised to $10.84 / share. This is an increase of 48.75% from the prior estimate of $7.29 dated September 27, 2025. The price target is an average of many targets provided by analysts. The ...

Repl.it is a start-up whose technology lets software engineers quickly write and ship code from a web browser. The start-up has raised a $4.5 million round of initial funding led by Andreessen ...

REPL EFFECT: Repl.it, an online programming and computing platform, has raised $4.5 million in a seed round led by two general partners, Marc Andreessen and Andrew Chen, from the venture capital firm ...